Luminex Announces Full Commercial Launch of the High-Throughput FLEXMAP 3D™ Multiplexing System
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Luminex Corporation has announced the full market release of its FLEXMAP 3D™ system, a high-throughput multiplexing instrument that allows scientists to simultaneously perform up to 500 tests on a single sample.
Created with input from scientists worldwide, FLEXMAP 3D was designed to meet the needs of medium and high-volume laboratories, such as academic, reference and pharmaceutical research laboratories.
The FLEXMAP 3D multiplexing system’s ability to conduct many tests at once can significantly enhance the efficiencies of life sciences research and drug discovery.
“We’re very excited about the full market launch of FLEXMAP 3D. This system was created for scientists who were seeking a faster throughput instrument with higher multiplexing capability. It will fill a vital need in high-volume laboratories and allow scientists to significantly increase their productivity,” said Patrick J. Balthrop, Sr., president and chief executive officer of Luminex. “FLEXMAP 3D is an important advancement in our goal to create multiplexing solutions for a range of applications and for laboratories of all sizes.”
Based on Luminex’s flexible xMAP® Technology, FLEXMAP 3D fills an essential segment between the low multiplex marketplace and the high multiplex microarray market.
The system can provide scientists at medium and high volume laboratories enhanced throughput, higher multiplexing, with up to 500 analytes per well, improved analytical performance, 96 or 384 well plate format, enhanced dual pipetting, automation and LIS compatibility, streamlined calibration and performance verification routines and easy maintenance with a simple workflow.
FLEXMAP 3D can perform multiplexed genomic, transcriptomic, and proteomic biomarker analysis on a single platform. FLEXMAP 3D is ideal for applications such as SNP genotyping and gene expression analysis. The system allows faster screening of novel targets and an overall improvement in laboratory management.
Created with input from scientists worldwide, FLEXMAP 3D was designed to meet the needs of medium and high-volume laboratories, such as academic, reference and pharmaceutical research laboratories.
The FLEXMAP 3D multiplexing system’s ability to conduct many tests at once can significantly enhance the efficiencies of life sciences research and drug discovery.
“We’re very excited about the full market launch of FLEXMAP 3D. This system was created for scientists who were seeking a faster throughput instrument with higher multiplexing capability. It will fill a vital need in high-volume laboratories and allow scientists to significantly increase their productivity,” said Patrick J. Balthrop, Sr., president and chief executive officer of Luminex. “FLEXMAP 3D is an important advancement in our goal to create multiplexing solutions for a range of applications and for laboratories of all sizes.”
Based on Luminex’s flexible xMAP® Technology, FLEXMAP 3D fills an essential segment between the low multiplex marketplace and the high multiplex microarray market.
The system can provide scientists at medium and high volume laboratories enhanced throughput, higher multiplexing, with up to 500 analytes per well, improved analytical performance, 96 or 384 well plate format, enhanced dual pipetting, automation and LIS compatibility, streamlined calibration and performance verification routines and easy maintenance with a simple workflow.
FLEXMAP 3D can perform multiplexed genomic, transcriptomic, and proteomic biomarker analysis on a single platform. FLEXMAP 3D is ideal for applications such as SNP genotyping and gene expression analysis. The system allows faster screening of novel targets and an overall improvement in laboratory management.
